均瑶健康(605388) - 2025 Q3 - 季度财报

Financial Performance - Total revenue for Q3 2025 was CNY 328,718,538.30, a decrease of 21.91% compared to the same period last year[4] - The total profit for the period was a loss of CNY 18,544,505.93, representing a decline of 213.62% year-on-year[4] - Net profit attributable to shareholders was a loss of CNY 9,834,901.33, down 167.09% from the previous year[4] - The basic earnings per share for the period was -CNY 0.0164, a decrease of 166.40% compared to the same period last year[5] - The company experienced a 365.11% decline in net profit after deducting non-recurring gains, totaling a loss of CNY 13,203,863.10 for the period[4] - Net profit attributable to shareholders for the current reporting period decreased to -167.09 million RMB, reflecting a significant drop in total profit[10] - Basic and diluted earnings per share for the current reporting period were both -166.3968 RMB, indicating a decline due to reduced total profit[10] - Net profit for the first three quarters of 2025 was a loss of CNY 11,371,197.00, compared to a profit of CNY 47,039,358.08 in 2024[28] - The company's operating profit for the first three quarters of 2025 was a loss of CNY 15,427,359.49, down from a profit of CNY 64,980,494.86 in the same period of 2024[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,017,573,820.66, a decrease of 12.79% from the end of the previous year[5] - The total liabilities decreased to CNY 319,056,799.83 in 2025 from CNY 548,716,746.59 in 2024, a reduction of 41.8%[24] - The total assets decreased to CNY 2,017,573,820.66 in 2025 from CNY 2,313,498,343.10 in 2024, a decline of 12.7%[24] - The company's equity attributable to shareholders decreased to CNY 1,715,649,397.36 in 2025 from CNY 1,772,911,604.62 in 2024, a decrease of 3.2%[24] Cash Flow - The cash flow from operating activities for the year-to-date was -CNY 87,189,611.93[4] - Cash inflow from sales of goods and services for the first three quarters of 2025 was $1,125,447,051.37, an increase of 5.76% compared to $1,064,200,690.63 in the same period of 2024[30] - Net cash flow from operating activities for the first three quarters of 2025 was -$87,189,611.93, compared to -$77,301,998.80 in 2024, indicating a decline in operational cash flow[30] - Total cash inflow from investment activities in the first three quarters of 2025 was $117,867,191.27, down from $172,694,409.60 in 2024, reflecting a decrease of 31.73%[31] - Net cash flow from investment activities improved to $48,856,444.18 in 2025, compared to -$106,178,718.47 in 2024, showing a significant recovery[31] - Cash inflow from financing activities totaled $48,153,848.80 in 2025, compared to $16,330,000.00 in 2024, marking a substantial increase of 194.56%[31] - The net cash flow from financing activities was -$52,088,707.44 in 2025, an improvement from -$87,380,733.01 in 2024[31] - The ending cash and cash equivalents balance for the first three quarters of 2025 was $135,448,848.48, down from $189,092,090.84 in 2024[31] Business Operations - The company reported a significant decline in probiotic beverage business revenue due to ongoing consumer demand pressures and market share loss in the dairy beverage sector[9] - The company's probiotic beverage revenue declined, leading to a year-on-year profit decrease of 213.62%[10] - The company is optimizing its revenue structure, with new product lines developing rapidly despite increased sales and marketing expenses[10] - The company’s overall operations showed resilience, with a commitment to technological innovation and quality improvement[14] - The company's probiotic food revenue reached 228 million RMB in the first three quarters of 2025, representing a year-on-year growth of 60.32%[15] - Online business saw a significant increase, with e-commerce sales growing by 120.84% compared to the same period last year[15] - The overseas channel business grew by 72.20% year-on-year, with products now covering over 80 countries and regions globally[15] - The probiotic business, as a core growth driver, achieved a revenue increase of 33.29% year-on-year[17] - The U.S. market showed strong performance, contributing nearly half of the overseas revenue, with significant order increases from key clients[19] - The company has successfully entered the pharmacy sector with its probiotic products, marking a new breakthrough in terminal coverage[21] Research and Development - The company increased R&D expenses, expanding its functional strain resource library to 50,000 strains, and launched a low-temperature probiotic beverage[10] - Research and development investment reached 28.41 million RMB in the first three quarters of 2025, marking a 20% increase compared to the previous year[17] - The company established a proprietary strain library of over 50,000 strains and created a "Six-Diamond" selection standard for quality benchmarks[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,338, with no preferred shareholders recovering voting rights[12] - The largest shareholder, Shanghai Junyao Group, holds 196,632,002 shares, representing 32.75% of the total shares[13] Accounting Standards - The company will not apply new accounting standards starting from 2025, as stated in the announcement[32]